Xconomy

From Amylin CEO, Putting Boardroom Coup Behind Him, Turns Up Heat on New Diabetes Drug:

bradbury
bradbury

Amylin Pharmaceuticals CEO Dan Bradbury

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.